2026 ICD-10-CM Diagnosis Code D69.6Thrombocytopenia, unspecified

ICD-10-CM CodesD50–D89D65-D69D69

ICD-10-CM D69.6
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

D69.6 is a billable ICD-10-CM diagnosis code for thrombocytopenia, unspecified. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 813. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Coagulation and hemorrhagic disorders.

D69.6 no longer risk-adjusts for Medicare Advantage: it mapped to HCC 48 under the retired CMS-HCC V24 model through payment year 2025 but maps to no category in the live V28 model. It still risk-adjusts in the PACE (CMS-HCC V22) category 48, ESRD (V21) category 48, and ESRD (V24) category 48 for payment year 2026.

Code Identity

ICD-10-CM Code
D69.6
Billable Status
Yes — Valid for Submission
Code Describes
Thrombocytopenia, unspecified
Short Description
Thrombocytopenia, unspecified
Same as the full description in the CMS dataset.
Parent Code
Purpura and other hemorrhagic conditions

Code Classification

ChapterD50–D89Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
SectionD65-D69Coagulation defects, purpura and other hemorrhagic conditions
CategoryD69Purpura and other hemorrhagic conditions
This CodeD69.6Thrombocytopenia, unspecified

Medicare Risk Adjustment (HCC)Billing

D69.6 no longer risk-adjusts for Medicare Advantage: it maps to no payment category in the live CMS-HCC V28 model, although it still risk-adjusts in the other CMS models shown below.

CMS-HCC V28 (Medicare Advantage Payment Model)
Not mapped
Dropped in V28 see all codes that no longer risk-adjust
Prior Model (CMS-HCC V24)
HCC 48
V24 retired last contributed to a Medicare Advantage risk score in payment year 2025
Other CMS Models
PACE (CMS-HCC V22): HCC 48 · ESRD (V21): HCC 48 · ESRD (V24): HCC 48
ESRD V21 weights: 0.059 dialysis, 0.173–0.234 functioning graft · ESRD V24 weights: 0.063 dialysis, 0.192–0.358 functioning graft
Part D (RxHCC)
Not mapped
D69.6 does not risk-adjust in the RxHCC prescription drug model

Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Acquired thrombocytopenia
  • Anasarca
  • Autoimmune thrombocytopenia in pregnancy
  • Febrile leukopenia
  • Immune thrombocytopenia
  • Isolated thrombocytopenia
  • Macrothrombocytopenia with mitral valve insufficiency
  • Myelodysplastic syndrome with low blasts
  • Refractory thrombocytopenia
  • Severe fever with thrombocytopenia syndrome
  • TAFRO syndrome
  • Thrombocytopenic disorder
  • Thrombocytopenic purpura due to defective platelet production

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR BLD006
Coagulation and hemorrhagic disorders
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Jacobsen Distal 11q Deletion Syndrome

    a clinically recognized congenital malformation condition caused by a distal 11q deletion. the features of the syndrome are growth retardation, psychomotor retardation, trigonocephaly, divergent intermittent strabismus, epicanthus, telecanthus, broad nasal bridge, short nose with anteverted nostrils, carp-shaped upper lip, retrognathia, low-set dysmorphic ears, bilateral camptodactyly, and hammertoes. platelet dysfunction is a feature in paris-trousseau type thrombocytopenia.
  • Kasabach-Merritt Syndrome

    rapidly growing vascular lesion along the midline axis of the neck, upper trunk, and extremities that is characterized by consumption coagulopathy; thrombocytopenia; and hemolytic anemia. it is often associated with infantile kaposiform hemangioendothelioma and other vascular tumors such as tufted angioma.
  • Purpura, Thrombocytopenic, Idiopathic

    thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. it is mediated by immune mechanisms, in most cases immunoglobulin g autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. the disease is seen in acute (affecting children) and chronic (adult) forms.
  • Thrombocytopenia

    a subnormal level of blood platelets.
  • Thrombocytopenia, Neonatal Alloimmune

    a condition in newborns caused by immunity of the mother to platelet alloantigens on the fetal platelets. the platelets, coated with maternal antibodies, are destroyed and removed by the fetal mononuclear phagocyte system. affected infants may have intracranial hemorrhages.
  • Phlebovirus

    a genus of the family bunyaviridae comprising many viruses, most of which are transmitted by phlebotomus flies and cause phlebotomus fever. the type species is rift valley fever virus.
  • Severe Fever with Thrombocytopenia Syndrome

    a tick-borne infection with severe fever with thrombocytopenia syndrome bunyavirus of the genus phlebovirus. it is associated with fever, thrombocytopenia; leukocytopenia, and multiorgan dysfunction. it is found in parts of asia including china, japan, korea and vietnam and can be transmitted from infected domestic animals and humans.
  • Blood Platelets

    non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. they are mainly involved in blood coagulation.
  • Anasarca

    a condition that is characterized by the presence of generalized edema. causes include congestive heart failure, liver failure, renal failure, and severe malnutrition.
  • Thrombocytopenic Disorder

    a disorder of platelets characterized by a finding of low platelet concentrations (thrombocytopenia) typically below 50,000 platelets per microliter of blood.

Patient EducationClinical

Platelet Disorders

Platelets, also known as thrombocytes, are blood cells. They form in your bone marrow, a sponge-like tissue in your bones. Platelets play a major role in blood clotting. Normally, when one of your blood vessels is injured, you start to bleed.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert D69.6 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
287.5 Thrombocytopenia NOS
Exact Match The mapping is direct, with no qualifiers.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About D69.6Overview

What is the ICD-10 code for thrombocytopenia, unspecified?

The ICD-10-CM code for thrombocytopenia, unspecified is D69.6 (sometimes written as D696). It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

Is D69.6 (Purpura and other hemorrhagic conditions) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report thrombocytopenia, unspecified on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does D69.6 group to?

When thrombocytopenia, unspecified is the principal diagnosis on an inpatient stay, it groups to MS-DRG 813 (coagulation Disorders), which carries a relative weight of 1.5253. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of D69.6?

Under the General Equivalence Mappings, thrombocytopenia, unspecified converts to ICD-9-CM 287.5 (thrombocytopenia NOS). The mapping is a direct match.

Does D69.6 risk-adjust for Medicare Advantage payment?

Not for Medicare Advantage. D69.6 mapped to HCC 48 in the retired CMS-HCC V24 model, which last determined payment in 2025, but it maps to no category in the live V28 model; see all codes that no longer risk-adjust. It still risk-adjusts in the PACE (CMS-HCC V22) category 48 (Coagulation Defects and Other Specified Hematological Disorders), ESRD (V21) category 48 (Coagulation Defects and Other Specified Hematological Disorders), and ESRD (V24) category 48 (Coagulation Defects and Other Specified Hematological Disorders).